Trial Profile
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Measles mumps and rubella virus vaccine; Pneumococcal 10-valent vaccine conjugate; Pneumococcal vaccine conjugate
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Pharmacodynamics; Registrational
- Sponsors sanofi pasteur
- 15 Jan 2019 Status changed from not yet recruiting to recruiting.
- 28 Nov 2018 Planned End Date changed from 8 Jul 2021 to 1 Sep 2021.
- 28 Nov 2018 Planned primary completion date changed from 8 Jul 2021 to 1 Sep 2021.